

# Magnus Sjogren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8167374/publications.pdf>

Version: 2024-02-01

117  
papers

8,727  
citations

44069

48  
h-index

42399

92  
g-index

121  
all docs

121  
docs citations

121  
times ranked

10299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validating the Danish version of the Eating Disorder Quality of Life Scale (EDQLS) in anorexia nervosa. <i>Eating and Weight Disorders</i> , 2022, , 1.	2.5	0
2	Estimating the Effect of Motivational Interventions in Patients with Eating Disorders: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 577.	2.5	5
3	Anorexia Nervosa: Reduction in Depression during Inpatient Treatment Is Closely Related to Reduction in Eating Disorder Psychopathology. <i>Journal of Personalized Medicine</i> , 2022, 12, 682.	2.5	4
4	BMI at Discharge from Treatment Predicts Relapse in Anorexia Nervosa: A Systematic Scoping Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 836.	2.5	12
5	Treatment studies with cannabinoids in anorexia nervosa: a systematic review. <i>Eating and Weight Disorders</i> , 2021, 26, 407-415.	2.5	11
6	Cognitive improvement following weight gain in patients with anorexia nervosa: A systematic review. <i>European Eating Disorders Review</i> , 2021, 29, 402-426.	4.1	20
7	A Systematic Review and Meta-Analysis Finds Increased Blood Levels of All Forms of Ghrelin in Both Restricting and Binge-Eating/Purging Subtypes of Anorexia Nervosa. <i>Nutrients</i> , 2021, 13, 709.	4.1	19
8	Weight Gain in Adults with Avoidant/Restrictive Food Intake Disorder Compared to Restrictive Anorexia Nervosa—Pilot Findings from a Longitudinal Study. <i>Nutrients</i> , 2021, 13, 871.	4.1	7
9	Cognitive Function in Adults with Enduring Anorexia Nervosa. <i>Nutrients</i> , 2021, 13, 859.	4.1	12
10	Explanatory Factors for Disease-Specific Health-Related Quality of Life in Women with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2021, 10, 1592.	2.4	4
11	Dialectical Behaviour Therapy Improves Emotion Dysregulation Mainly in Binge Eating Disorder and Bulimia Nervosa: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 931.	2.5	20
12	Inpatient Weight Restoration Treatment Is Associated with Decrease in Post-Meal Anxiety. <i>Journal of Personalized Medicine</i> , 2021, 11, 1079.	2.5	6
13	Why Do Women with Eating Disorders Decline Treatment? A Qualitative Study of Barriers to Specialized Eating Disorder Treatment. <i>Nutrients</i> , 2021, 13, 4033.	4.1	3
14	Study protocol of comprehensive risk evaluation for anorexia nervosa in twins (CREAT): a study of discordant monozygotic twins with anorexia nervosa. <i>BMC Psychiatry</i> , 2020, 20, 507.	2.6	6
15	Comorbid depression as a negative predictor of weight gain during treatment of anorexia nervosa: A systematic scoping review. <i>European Eating Disorders Review</i> , 2020, 28, 605-619.	4.1	30
16	Potential shortcomings in current studies on the effect of intranasal oxytocin in Anorexia Nervosa and healthy controls - A systematic review and meta-analysis. <i>Psychopharmacology</i> , 2020, 237, 2891-2903.	3.1	5
17	Case report: cognitive performance in an extreme case of anorexia nervosa with a body mass index of 7.7. <i>BMC Psychiatry</i> , 2020, 20, 284.	2.6	5
18	Sexual function and dysfunction among women with anorexia nervosa: A systematic scoping review. <i>International Journal of Eating Disorders</i> , 2020, 53, 1377-1399.	4.0	12

#	ARTICLE	IF	CITATIONS
19	Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and meta-analysis. <i>International Journal of Eating Disorders</i> , 2019, 52, 611-629.	4.0	38
20	Dysbiosis of the Microbiota in Anorexia Nervosa: Pathophysiological Implications. , 2019, , .		0
21	A systematic review of blood-based serotonergic biomarkers in Bulimia Nervosa. <i>Psychiatry Research</i> , 2019, 279, 155-171.	3.3	5
22	On motivation as a Target for Intervention in Anorexia Nervosa. <i>Archives in Neurology &amp; Neuroscience</i> , 2019, 5, .	0.2	1
23	A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine. <i>Eating and Weight Disorders</i> , 2018, 23, 399-418.	2.5	33
24	Anorexia Nervosa and Motivation for Behavioral Change - Can it be Enhanced?. <i>Journal of Psychology &amp; Clinical Psychiatry</i> , 2017, 8, .	0.1	2
25	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- $\beta$ concentrations collected by lumbar puncture and indwelling lumbar catheter. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 53.	6.2	22
26	Effect of diagnostic criteria on prevalence of frontotemporal dementia in the elderly. <i>Alzheimer's and Dementia</i> , 2015, 11, 425-433.	0.8	8
27	A Brief Review of the Biology of Anorexia Nervosa. <i>Journal of Psychology &amp; Clinical Psychiatry</i> , 2015, 4, .	0.1	0
28	The Diagnostic Work-Up of Eating Disorders. <i>Journal of Psychology &amp; Clinical Psychiatry</i> , 2015, 4, .	0.1	0
29	Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population. <i>Current Alzheimer Research</i> , 2014, 11, 40-46.	1.4	6
30	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 163-171.	1.5	4
31	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.8	250
32	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.8	138
33	Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 611-621.	2.6	18
34	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. <i>Neuropsychopharmacology</i> , 2012, 37, 1036-1046.	5.4	58
35	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <i>Neurobiology of Aging</i> , 2012, 33, 831.e1-831.e9.	3.1	36
36	Evaluation of the Glycine Transporter Inhibitor Org 25935 as Augmentation to Cognitive-Behavioral Therapy for Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 647-653.	2.2	18

#	ARTICLE	IF	CITATIONS
37	Apathy is a prominent neuropsychiatric feature of radiological white matter changes in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 588-595.	2.7	50
38	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 124-125.	1.9	8
39	Secular changes in cognitive predictors of dementia and mortality in 70-year-olds. <i>Neurology</i> , 2010, 75, 779-785.	1.1	51
40	The Cerebrospinal Fluid Amyloid $\beta$ 42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia. <i>Current Alzheimer Research</i> , 2010, 7, 470-476.	1.4	120
41	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports. <i>Case Reports in Neurology</i> , 2010, 2, 5-11.	0.7	3
42	Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent. <i>European Geriatric Medicine</i> , 2010, 1, 58-63.	2.8	26
43	The use of indexes in the interpretation of cerebrospinal fluid analyses. <i>Neurobiology of Aging</i> , 2010, 31, 1654.	3.1	0
44	Cerebrospinal Fluid $\beta$ -Synuclein Does Not Discriminate Between Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 363-369.	2.6	87
45	The pattern of cognitive symptoms predicts time to dementia onset. <i>Alzheimer's and Dementia</i> , 2009, 5, 199-206.	0.8	16
46	Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer's Disease Patients and Healthy Individuals. <i>Neurochemical Research</i> , 2008, 33, 1332-1340.	3.3	95
47	Small heat shock proteins Hsp27 or $\beta$ -crystallin and the protein components of neurofibrillary tangles: Tau and neurofilaments. <i>Journal of Neuroscience Research</i> , 2008, 86, 1343-1352.	2.9	73
48	Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. <i>Current Opinion in Psychiatry</i> , 2008, 21, 555-561.	6.3	41
49	Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid $A\beta$ 242 in Late Life. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 30-36.	1.3	20
50	Frontotemporal dementia – A brief review. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 180-187.	4.6	23
51	Cholesterol and Alzheimer's disease – is there a relation?. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 138-147.	4.6	86
52	Proteome studies of CSF in AD patients. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 133-137.	4.6	40
53	Assessments of the accumulation severities of amyloid $\beta$ 2-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. <i>Neurobiology of Disease</i> , 2006, 22, 657-668.	4.4	55
54	Depressive symptoms and white matter changes in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 119-125.	2.7	27

#	ARTICLE	IF	CITATIONS
55	Vagus Nerve Stimulation in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1171-1178.	2.2	165
56	Zinc induces neurofilament phosphorylation independent of p70 S6 kinase in N2a cells. <i>NeuroReport</i> , 2005, 16, 591-595.	1.2	31
57	The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases. <i>Disease Markers</i> , 2005, 21, 81-92.	1.3	90
58	The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1485-1490.	1.9	156
59	Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. <i>Neurology</i> , 2005, 65, 1894-1900.	1.1	34
60	High total cholesterol levels in late life associated with a reduced risk of dementia. <i>Neurology</i> , 2005, 64, 1689-1695.	1.1	346
61	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 256-265.	1.5	86
62	The link between cholesterol and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 85-97.	2.6	54
63	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95.	12.3	390
64	Negative Neurofilament Light and Tau Immunostaining in Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 346-349.	1.5	3
65	Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 197-206.	1.5	38
66	Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. <i>Journal of Psychiatric Research</i> , 2004, 38, 113-121.	3.1	161
67	HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment refractory depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 349-355.	3.2	27
68	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <i>Clinical Biochemistry</i> , 2004, 37, 230-237.	1.9	43
69	Proteomics for drug target discovery. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2004, 73, 47-53.	3.5	18
70	P3-241 Zinc induces phosphorylation of neurofilament proteins in mouse N2A neuroblastoma cells. <i>Neurobiology of Aging</i> , 2004, 25, S423.	3.1	0
71	Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. <i>Proteome Science</i> , 2004, 2, 7.	1.7	45
72	Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. <i>Acta Neuropathologica</i> , 2003, 105, 469-476.	7.7	51

#	ARTICLE	IF	CITATIONS
73	Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness. <i>Journal of Affective Disorders</i> , 2003, 74, 185-189.	4.1	22
74	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 132-136.	2.9	69
75	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 520-526.	2.9	55
76	Measurement of $\beta$ - and $\beta$ -secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. <i>Experimental Neurology</i> , 2003, 183, 74-80.	4.1	114
77	Advances in the detection of Alzheimer's disease—use of cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2003, 332, 1-10.	1.1	57
78	Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. <i>Neuroscience Letters</i> , 2003, 340, 69-73.	2.1	28
79	Classification and Subtypes of Vascular Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 27-37.	1.0	39
80	Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both $\beta$ - and $\beta$ -Cleaved Amyloid Precursor Protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 25-30.	1.5	102
81	CSF markers for Alzheimer's disease: Total tau, phospho-tau and $\beta$ 42. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 147-155.	2.6	108
82	Treatment of Aggressive Behavior in Dementia With the Anticonvulsant Topiramate: A Retrospective Pilot Study. <i>International Psychogeriatrics</i> , 2003, 15, 307-309.	1.0	29
83	Objective Measurement of the Alertness Level in Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 212-217.	1.5	7
84	Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 200-207.	1.5	41
85	Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. <i>NeuroReport</i> , 2002, 13, 611-615.	1.2	190
86	Decreased CSF- $\beta$ -Amyloid 42 in Alzheimer's Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of $\beta$ -Amyloid Induced by Disparate Mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 112-118.	1.5	125
87	Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. <i>Molecular Brain Research</i> , 2002, 109, 128-133.	2.3	95
88	Increased intrathecal levels of the angiogenic factors VEGF and TGF- $\beta$ in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> , 2002, 23, 237-243.	3.1	329
89	Biological Correlates of Clinical Subgroups of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 191-197.	1.5	13
90	Relationship between depressive symptomatology and the subcortical brain syndrome in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 774-778.	2.7	17

#	ARTICLE	IF	CITATIONS
91	Cognition-Enhancing Effect of Vagus Nerve Stimulation in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 972-980.	2.2	170
92	Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E $\epsilon$ 4 Frequency, but No Tau Gene Mutations. <i>Experimental Neurology</i> , 2001, 168, 413-418.	4.1	70
93	Low cerebrospinal fluid $\beta$ -amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. <i>Neuroscience Letters</i> , 2001, 314, 33-36.	2.1	71
94	EDRF transcripts and diagnosis of variant Creutzfeldt-Jakob disease. <i>Lancet</i> , The, 2001, 357, 2069-2070.	13.7	6
95	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264.	1.5	102
96	Tacrine and rate of progression in Alzheimer's disease - relation to ApoE allele genotype. <i>Journal of Neural Transmission</i> , 2001, 108, 451-458.	2.8	50
97	The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. <i>Acta Ophthalmologica</i> , 2001, 79, 283-285.	0.3	95
98	Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. <i>Journal of Neuroscience Research</i> , 2001, 66, 510-516.	2.9	175
99	Pathophysiological aspects of frontotemporal dementia - emphasis on cytoskeleton proteins and autoimmunity. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1923-1935.	4.6	24
100	Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1937-1949.	4.6	51
101	Treatment of Alzheimer's Disease with Clioquinol. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 408-414.	1.5	202
102	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.	2.0	1,506
103	Frontotemporal Dementia Can Be Distinguished from Alzheimer's Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 275-285.	1.5	60
104	Oral d-fenfluramine test in treatment-refractory depression. <i>Journal of Affective Disorders</i> , 2000, 57, 201-208.	4.1	11
105	CSF levels of tau, $\beta$ -amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , 2000, 107, 563-579.	2.8	227
106	Frontotemporal dementia - Clinical and pathophysiological aspects. <i>Nordic Journal of Psychiatry</i> , 2000, 54, 149-150.	1.3	0
107	Symptoms, Vascular Risk Factors and Blood-Brain Barrier Function in Relation to CT White-Matter Changes in Dementia. <i>European Neurology</i> , 2000, 44, 229-235.	1.4	85
108	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. <i>Neuroscience Letters</i> , 2000, 285, 49-52.	2.1	452

#	ARTICLE	IF	CITATIONS
109	Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998, 19, 379-384.	3.1	80
110	Longitudinal EEG Findings in Dementia Related to the Parietal Brain Syndrome and the Degree of Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 199-204.	1.5	6
111	The apolipoprotein E $\epsilon$ 4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. <i>Neuroscience Letters</i> , 1997, 226, 65-67.	2.1	55
112	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	2.7	40
113	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	2.7	3
114	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 185-199.	2.3	84
115	Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. <i>Biological Psychiatry</i> , 1995, 38, 210-216.	1.3	42
116	Cytosolic free calcium elevation mediates the phagosome-lysosome fusion during phagocytosis in human neutrophils. <i>Journal of Cell Biology</i> , 1990, 110, 1555-1564.	5.2	235
117	Cortisol, Depression, and Anxiety Levels Before and After Short-Term Intensive Nutritional Stabilization in Patients With Severe Anorexia Nervosa. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	5